Bryce Point Capital LLC Makes New $469,000 Investment in Kenvue Inc. (NYSE:KVUE)

Bryce Point Capital LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 21,958 shares of the company's stock, valued at approximately $469,000.

A number of other institutional investors and hedge funds also recently modified their holdings of KVUE. Handelsbanken Fonder AB raised its stake in Kenvue by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after acquiring an additional 21,222 shares during the period. Alberta Investment Management Corp raised its position in shares of Kenvue by 23.2% during the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after purchasing an additional 109,700 shares during the period. Longbow Finance SA lifted its holdings in shares of Kenvue by 5.0% in the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company's stock worth $5,990,000 after purchasing an additional 13,287 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in Kenvue by 143.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after purchasing an additional 28,216 shares during the period. Finally, CORDA Investment Management LLC. grew its stake in Kenvue by 1.4% during the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock worth $26,754,000 after buying an additional 17,466 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Kenvue Stock Performance

Shares of KVUE traded down $0.04 during mid-day trading on Thursday, hitting $21.74. The company's stock had a trading volume of 5,720,085 shares, compared to its average volume of 16,875,128. The stock's 50-day moving average is $22.61 and its two-hundred day moving average is $22.42. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a market capitalization of $41.56 billion, a PE ratio of 40.93, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.77%. The ex-dividend date was Wednesday, February 12th. Kenvue's payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

Several research firms have recently commented on KVUE. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and lowered their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Redburn Atlantic initiated coverage on shares of Kenvue in a research note on Thursday. They issued a "neutral" rating and a $23.50 price target on the stock. Barclays boosted their price objective on Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Thursday, March 27th. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 15th. Finally, Evercore ISI assumed coverage on Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Kenvue currently has a consensus rating of "Hold" and a consensus target price of $23.96.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.